AzTrials
AzTrials

Anterior Cruciate Ligament InjuriesNCT04495075

Neuromuscular Control in Individuals Following ACL-Reconstruction

A study testing Visuomotor Therapy and Passive Motion in people with Anterior Cruciate Ligament Injuries and Quadriceps Muscle Atrophy, run by University of Virginia at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate the neurophysiological contributors to muscle function following ACL Reconstruction and the influence of motor control biofeedback exercise on measures of muscle function. Read more about this study

Who is it for?
Ages 18 to 45 years
What is being tested?
Visuomotor Therapy and Passive Motion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
1 Mar 2019to 1 Mar 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • • Ages 18-45
  • At the time point of return to play progression following ACL Reconstruction
  • Physically active individuals based on current ACSM guidelines of 30 minutes of moderate-intensity daily physical activity three days a week)

Who cannot join

  • Subjects who are known to be pregnant (self-reported)
  • Subjects diagnosed with malignancy
  • Subjects with serious infection near the lower limb
  • Subjects with known muscular abnormalities
  • History of cardiopulmonary disorder
  • Subjects with a previous history of stroke
Show all 15Show fewer
  • History of neurological or psychiatric disorders including poorly controlled migraine headaches, seizure disorder, history or immediate family history of seizures and/or epilepsy
  • Subjects with any type of neuropathy (numbness and tingling)
  • Subjects with a clinical diagnosis of multiple sclerosis (MS) or Parkinson's Disease
  • Implanted biomedical device (active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, and vagus nerve stimulators)
  • History of skull fracture
  • Subjects who have any metal implants anywhere in their head, neck or shoulders
  • Patients taking any medications, which may influence cortical excitability, which could influence neurophysiologic measures) and affect objective clinical data (e.g. antispastics, anxiolytics, hypnotics, ant-epileptics)
  • Subjects who are prescribed medications which may influence cortical excitability, which could influence neurophysiologic measures) and affect objective clinical data (e.g. antispastics, anxiolytics, hypnotics, ant-epileptics), will not be able to remain in the study.
  • Unable to provide consent.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Virginia

    Charlottesville, Virginia, 22903

Other trials in United States

About this study

Official title: The Use of Visuomotor Therapy to Modulate Corticospinal Excitability in Patients Following ACL-Reconstruction

The purpose of this study is to investigate the neurophysiological contributors to muscle function following ACL Reconstruction and the influence of motor control biofeedback exercise on measures of muscle function. The research team hypothesizes that the application of motor biofeedback will increase cortical excitability of the quadriceps compared to the passive movement of the knee.

This is a single session cross-over intervention study with a 1-week washout period between treatment arms.

Read the detailed description
  1. Pre-treatment neuromuscular assessment Cortical Active Motor Threshed We will measure motor evoked potentials with the use of a Transcranial magnetic stimulator (MagStim model 200, Magstim Co., Ltd., Wales, UK). The MagStim has FDA 510K Clearance for stimulation of peripheral nerves.
  • The participant will be asked to sit in the dynamometer (Biodex, System 3) in knee extension at 90 degrees of knee flexion.
  • EMG electrodes will be placed on the distal quadriceps
  • Local shaving, debridement, and cleaning will be done prior if necessary
  • A non-latex swim cap will be placed on the participants head for investigator's measurements
  • Briefly, a magnetic field with a maximum value of 2.2 Tesla will be introduced to the scalp at a location in the pre-motor cortex that corresponds to the quadriceps. Single pulse stimulations will be delivered with no less than 10 seconds between stimulations (maximum = 0.1 Hz).
  • When the magnetic field is received at the premotor cortex at the appropriate area, a motor signal is sent to the quadriceps. We will record this signal with surface EMG electrodes that are on the quadriceps.
  • The participant will be asked to extend their leg to match a force equivalent to 5% MVIC. Feedback will be provided to the participant to provide such force.
  • Stimulation of the TMS will happen once every ten seconds until the Active Motor Threshold was found by the investigator.
  • The motor evoked potential measured by the quadriceps will be recorded at 80%, 90%, 100%, 110%, 120%, 130%, 140%, and 150% of the patients Active motor threshold.
  1. Patient randomization
  • The patient is then randomized to 1 of 2 treatment arms. 1) Visuomotor Therapy or 2) Passive Motion
  1. Perform Randomized Treatment Visuomotor Therapy
  • The participant will sit in the Biodex chair with the tested limb secured in the dynamometer
  • The participant will receive live real-time biofeedback of their knee force output (no more than 30% of maximum force)
  • The participant will aim to match their force output to a target threshold presented on the screen.
  • The participant will complete 10 60-second trials of this exercise with a 30 second rest between each trial. OR Passive Motion
  • The participant will sit in the Biodex chair with the tested limb secured in the dynamometer
  • The dynamometer will passively move the patients lower limb between 80 to 120 degrees of knee flexion
  • The participant will be asked to relax for the duration of testing - The participant will complete 10 60-second trials of this exercise with a 30 second rest between each trial.
  1. Reassess Neuromuscular outcome (Step 1)
  2. 1-week washout period
  3. Repeat Steps 1 through 4 but the patient receives the cross-over arm intervention
Being tested
Visuomotor Therapy, Passive Motion
Medical subject headings
Anterior Cruciate Ligament Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Visuomotor TherapyOther

    Also called Motor Biofeedback

    The use of visual feedback informing internal physiological processes, such as muscle activation, torque, and joint position, has been termed "visuomotor therapy". Visuomotor therapy encompasses completion of sub-maximal motor control tasks accompanying real-time visual biofeedback.

  • Passive MotionOther

    The knee is passively moved through a range of motion.

Study groups in NCT04495075
Study groupRoleWhat they receive
Visuomotor TherapyExperimentalPatients were seated in the isokinetic dynamometer with their hips flexed to 85º. A target sine wave with a maximum amplitude of 30% MVIC and a minimum amplitude of 5% MVIC and a frequency of 0.128 Hz was visually presented to the patient.31 The patient was instructed to match their torque to the presented target throughout the duration of testing. Each visuomotor therapy trial was 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes.
Receives: Other: Visuomotor Therapy
Passive MotionActive comparatorPatients were seated in the isokinetic dynamometer with their hips flexed to 85º. The dynamometer then passively moved the patient from 80º to 120º of knee flexion for 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes. The patient was provided visual feedback of their knee position throughout the trials. The patient was instructed to relax their knee throughout the intervention.
Receives: Other: Passive Motion

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quadriceps Motor Evoked Potential (micoVolts) PreSham (Passive Motion)

    Activation of the Quadriceps muscle through stimulation of primary motor cortex. Measured Through electromyography on the vastus medialis

    Measured: 6-months post-Anterior Cruciate Ligament Reconstruction

  2. Quadriceps Motor Evoked Potential (micoVolts) PostSham (Passive Motion)

    Activation of the Quadriceps muscle through stimulation of primary motor cortex. Measured Through electromyography on the vastus medialis

    Measured: 6-months post-Anterior Cruciate Ligament Reconstruction

  3. Change in Quadriceps Motor Evoked Potential - Sham (Passive Motion)

    Difference in microVolts between pre-sham measure and post-sham measure

    Measured: 6-months post-Anterior Cruciate Ligament Reconstruction

  4. Quadriceps Motor Evoked Potential (micoVolts) PreActive (Visuomotor Therapy)

    Activation of the Quadriceps muscle through stimulation of primary motor cortex. Measured Through electromyography on the vastus medialis

    Measured: 6-months post-Anterior Cruciate Ligament Reconstruction

  5. Quadriceps Motor Evoked Potential (micoVolts) PostActive (Visuomotor Therapy)

    Activation of the Quadriceps muscle through stimulation of primary motor cortex. Measured Through electromyography on the vastus medialis

    Measured: 6-months post-Anterior Cruciate Ligament Reconstruction

  6. Change in Quadriceps Motor Evoked Potential - Active (Visuomotor Therapy)

    Difference in microVolts between pre-active measure and post-active measure

    Measured: 6-months post-Anterior Cruciate Ligament Reconstruction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2020
  2. Study start1 Mar 2019
  3. Primary completion1 Mar 2020
  4. Study completion1 Mar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
Laboratory Controlled Crossover Study
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04495075
Sponsor's protocol ID
20441
Status last verified
Jul 2020
First submitted
21 Jul 2020
Last updated
31 Jul 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Visuomotor Therapy and Passive Motion in people with Anterior Cruciate Ligament Injuries and Quadriceps Muscle Atrophy, run by University of Virginia at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quadriceps Motor Evoked Potential (micoVolts) PreSham (Passive Motion) (time frame: 6-months post-Anterior Cruciate Ligament Reconstruction). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in